HONZ(SZ:300086)2018-08-20 16:00Financial Performance - Total operating revenue for the reporting period reached ¥274,168,177.92, an increase of 18.09% compared to ¥232,165,969.33 in the same period last year[19]. - Net profit attributable to shareholders of the listed company was ¥36,231,464.17, up 13.79% from ¥31,840,887.88 year-on-year[19]. - Net profit after deducting non-recurring gains and losses increased by 57.20%, reaching ¥22,777,403.31 compared to ¥14,489,846.64 in the previous year[19]. - Basic earnings per share rose to ¥0.0805, reflecting a 13.70% increase from ¥0.0708[19]. - The company reported stable operations and good financial condition, focusing on cost control and cash management[32]. - Significant contributions to performance came from children's diarrhea and digestion products, cough relief products, and cold series products, supported by relevant policies[32]. - The company achieved operating revenue of 274.17 million yuan, an increase of 18.09% compared to the same period last year[54]. - The net profit attributable to shareholders was 36.23 million yuan, reflecting a growth of 13.79% year-on-year[54]. - Basic earnings per share reached 0.0805 yuan, up by 13.70% from the previous year[54]. Cash Flow and Investments - The net cash flow from operating activities was -¥66,314,244.29, a significant decrease of 1,273.10% from ¥5,652,919.74 in the same period last year[19]. - The company redeemed financial products, resulting in a 564.01% increase in net cash flow from investing activities to ¥254,254,022.43[63]. - The company’s cash and cash equivalents surged to ¥208,901,990.38 from ¥25,777,915.19 at the start of the period, marking a significant increase[182]. - Cash flow from operating activities shows a net outflow of ¥66,314,244.29, compared to a net inflow of ¥5,652,919.74 in the previous period[194]. - Cash flow from investing activities generated a net inflow of ¥254,254,022.43, recovering from a net outflow of ¥54,795,408.25 in the previous period[195]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥2,331,608,962.58, representing a 4.28% increase from ¥2,235,979,743.68 at the end of the previous year[19]. - Total liabilities increased from CNY 315,308,681.39 to CNY 374,807,785.16, an increase of about 18.8%[179]. - The company's equity attributable to shareholders increased from CNY 1,850,813,947.50 to CNY 1,887,045,411.67, an increase of about 2%[180]. - The total amount of raised funds was CNY 1,448.8 million, with CNY 981.5 million utilized by the end of the reporting period, accounting for 67.8% of the total[78]. Research and Development - The company is developing the world's first hand-foot-mouth disease treatment drug, with clinical trial applications accepted by the National Medical Products Administration[35]. - The company has advanced R&D capabilities and a strong team, enhancing its product quality and safety[30]. - The company’s research and development expenses increased by 81.50% to ¥8,756,501.85, reflecting a significant boost in R&D efforts[63]. - The company is actively engaged in research and development, as evidenced by its numerous patents related to drug formulations and delivery systems[41][42]. Acquisitions and Expansion - The company successfully acquired Yunnan Jiuzhou Hospital and He Wan Jia Hospital, marking its entry into the reproductive medicine sector[26]. - The company acquired 100% equity of Guangzhou Ruiling, indirectly holding 51% of Jiuzhou Hospital and Wanji Hospital, effective July 2018[33]. - The company is currently constructing its Guangdong production base, with phase one completed and phase two in the decoration stage[56]. - The company has invested RMB 220 million in the construction of the Kangzhi Industrial Park Project (Phase I) using excess raised funds[87]. Marketing and Sales - The company emphasizes a "new Kangzhi model" focusing on premium products and cooperative win-win principles in its marketing strategy[30]. - The sales network includes nearly 1,000 agents and over 40,000 sales terminals across the country[30]. - The company incurred sales expenses of ¥5,311,298.92, significantly higher than ¥951,252.37 in the previous period, indicating increased marketing efforts[189]. Corporate Governance and Compliance - The company has not reported any significant risks that could materially affect its operations during the reporting period[5]. - The semi-annual financial report for the company has not been audited[115]. - The company has not disposed of any significant assets or equity during the reporting period, indicating stability in its asset management[97]. - The company has adhered to all commitments made during the reporting period without any violations[112]. Social Responsibility - In the first half of 2018, the company raised a total of 127,780 RMB for the Kangzhi Red Face Fund through charity auctions, aimed at supporting underprivileged children[144]. - The company donated materials worth 25,000 RMB to establish a library at a primary school in Sichuan, enhancing educational resources for local children[144].